Neurological
Refine Search
Biotechnology
Belgian drugmaker UCB was trading more than 3% higher by lunchtime on Thursday after presenting its financial results for 2019. 20 February 2020
Pharmaceutical
At a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg) today, the non-profit non-governmental organization (NGO) Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies and setting out updated prevalence rates for dementia in Europe. 18 February 2020
Biotechnology
Independent drugmaker Servier and fellow France-based biotech Oncodesign (Euronext: ALONC) late Monday announced reaching an important milestone in their strategic partnership on potential drug candidates for Parkinson’s disease, news of which sent Oncodesign’s shares leaping 17% to 11.70 euros in early trading this morning. 18 February 2020
Pharmaceutical
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken by US biotech Tetra Therapeutics. 17 February 2020
Biotechnology
Shares of UK-based ReNeuron Group rose as much as 4% in early trading, as the company announced the publication in a peer reviewed journal of positive clinical data from the PISCES II Phase IIa clinical trial of its CTX stem cell therapy candidate for disability resulting from stroke. 17 February 2020
Pharmaceutical
Last week’s news included further disappointment for the Alzheimer’s community, with Eli Lilly’s solanezumab and Roche’s gantenerumab failing in their latest trials. There was also disappointment for Biohaven Pharmaceuticals’ troriluzole for generalized anxiety disorder (GAD). On a more positive note, US biotech Moderna saw a sharp rise it its market cap after it announced a positive development for its coronavirus vaccine. Regulatory news included US Food and Drug Administration acceptance for priority review of Bristol-Myers Squibb’s immune-oncology candidate lisocabtagene maraleucel (liso-cel). Also, Japan’s Eisai was obliged to withdraw its weight-loss drug Belviq from the US market. 16 February 2020
Pharmaceutical
UK drugmaker Indivior lost 20% of its market value on Thursday after reporting a $46 million adjusted operating loss for the latest quarter. 13 February 2020
Generics
Shares in Teva Pharmaceutical are up almost 7% in pre-market trading, as the Israeli generics giant reported better-than-expected fourth quarter revenues of $4.5 billion. 12 February 2020
Biotechnology
Cassava Sciences, a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal for the research community, published results from the company’s Phase IIa study demonstrating that its lead drug candidate, PTI-125, reduced biomarkers of disease in Alzheimer’s patients. 11 February 2020
Biotechnology
Shares in CNS specialist Biohaven Pharmaceutical were 8% down after an hour of trading on Monday. 10 February 2020
Biotechnology
Eli Lilly’s hopes that coming up with a new trial design might mean a different result for its Alzheimer’s candidate, solanezumab, have been dashed. 10 February 2020
Biotechnology
In a second disappointment for Roche in the search for a treatment for the devastating disease, the Swiss pharma giant today announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in people who have an early-onset, inherited form of Alzheimer’s disease (AD). 10 February 2020
Biosimilars
Last week’s news included Bristol-Myers Squibb deciding to pull its application with the European Medicines Agency for the combination of its top-selling drug Opdivo with Yervoy for certain cancer patients. US biotech Biogen had a boost last Wednesday when it prevailed in a patent dispute with Mylan over multiple sclerosis drug Tecfidera. On the research front and in the face of the ever-increasing impact of the coronavirus epidemic, Gilead Sciences joined the fight with its investigational antiviral remdesivir and entering trials in China, and GlaxoSmithKline linked up with the Coalition for Epidemic Preparedness Innovations. Last week also saw the US Food and Drug Administration and the Federal Trade Commission announce a cooperation on making biosimilars more accessible. And, along with its 2019 financial results, US pharma giant Merck & Co said it plans to spin out its established products into a new company. 9 February 2020
Biotechnology
Danish biopharma Orphazyme has raised 745 million Danish kroner ($109 million) in a directed issue and private placement. 7 February 2020
Biotechnology
New York-based biopharma Tonix Pharmaceuticals lost 40% of its value in Thursday morning’s trading. 6 February 2020
Pharmaceutical
Danish CNS specialist Lundbeck shares were down 2.3% at 295.40 Danish kroner by late morning today, after it released financial results for 2019, showing that revenues were down 6% at 17.14 billion Danish kroner ($2.53 billion), primarily driven by the loss of exclusivity of Lennox Gastaux syndrome drug Onfi (clobazam). 6 February 2020
Biotechnology
California, USA-based clinical-stage biotech CODA Biotherapeutics today announced it has completed the acquisition of Attenua. Financial terms of the transaction are not being disclosed. 5 February 2020
Pharmaceutical
Prosecutors in France have launched an investigation into Sanofi’s marketing of the drug Depakine (sodium valproate). 5 February 2020
Pharmaceutical
Japanese drugmaker Takeda closed 1% up after Tuesday’s Tokyo trading. 4 February 2020
Biotechnology
Israeli drugmaker Teva Pharmaceutical Industries and its partner for the Japanese market, Otsuka Pharmaceutical, have edged closer to approval for Ajovy (fremanezumab) in the Asian country. 3 February 2020
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze